BioMarin Pharmaceutical Inc.

Our Purpose

At BioMarin, we translate the promise of genetic discovery into medicines that make a profound impact on the life of each patient.

Since our founding in 1997, we’ve developed a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that offer new possibilities for people living with genetically defined conditions around the world.

As we have looked to expand our impact, our approach to cutting-edge science has remained the same. We enlist the best of the best – people with the right technical expertise and a relentless drive to solve real problems – and create an environment that empowers our teams to pursue bold, innovative science.

770 Lindaro Street
San Rafael, CA 94901

105 Digital Drive
Novato, CA 94949

Tel: (415) 506-6700

Visit website

NEWS

Job Trends

The Bay Area’s Top Life Science Companies by Median Pay

The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.

April 12, 2019

3 min read

Mark Terry

Lumasiran was granted priority review status by FD

Policy

Industry and Advocacy Groups Urge FDA to Allow More Real-World Data for Rare Disease Trials

In January 2019, the U.S. Food and Drug Administration (FDA) updated a 2015 draft guidance on rare diseases.

April 5, 2019

3 min read

Mark Terry

Drug Development

The 20 Hottest Pipeline Drugs to Watch in 2019

EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.

December 18, 2018

6 min read

Mark Terry

FDA

After 2016 Rejection, Catalyst Wins Approval for LEMS Treatment Firdapse

Florida-based Catalyst Pharma won regulatory approval for its treatment of a rare autoimmune disorder called Lambert-Eaton myasthenic syndrome (LEMS). The U.S. Food and Drug Administration approval of the new oral drug, Firdapse (amifampridine), is the first ever approved for this disease.

November 29, 2018

3 min read

Alex Keown

Drug Development

BioMarin Sponsors Off-Broadway Show About Hemophilia

‘Hemophilia: The Musical’ allows teens to share their experiences with the genetic disease.

November 21, 2018

2 min read

Alex Keown

Job Trends

BioSpace Movers and Shakers Oct. 29

Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.

October 26, 2018

4 min read

Alex Keown

Job Trends

Gene Therapy, Gene Editing and Immuno-Oncology Creating Thousands of New Job Opportunities

The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists.

October 19, 2018

5 min read

Mark Terry

Drug Development

Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week

Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.

October 18, 2018

6 min read

Alex Keown

Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.

FDA

FDA Approves Pfizer’s Talzenna for Breast Cancer

The U.S. FDA approved Pfizer’s PARP inhibitor, Talzenna (talazoparib), for patients with a germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The agency also approved Myriad Genetics’ diagnostic assay to identify the mutation.

October 17, 2018

2 min read

Mark Terry

JOBS